Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
about
Medical treatments in the short term management of reflux oesophagitisTreatment for Barrett's oesophagusMedical treatments in the short term management of reflux oesophagitisEvidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction.An open-label, non-comparative, non-interventional, multi-center, post-authorization safety study on the administration of rabeprazole to adults with gastro-esophageal reflux disease.Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapyReview of rabeprazole in the treatment of gastro-oesophageal reflux disease.Assessment of reflux symptom severity: methodological options and their attributes.Patient assessment of treatment satisfaction: methods and practical issuesReview article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.Review article: diagnosis and management of night-time reflux.Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease.A review of rabeprazole in the treatment of acid-related diseasesRabeprazole for the treatment of acid-related disorders.Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.Improvement of gastroesophageal reflux disease in Japanese patients with spinal kyphotic deformity who underwent surgical spinal correction.Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks.Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
P2860
Q24234225-18CF2EBD-E07E-4A99-B7F8-966391B47FCDQ24240701-A65AA5CE-751B-4DBA-9C7F-6827296A3303Q24245220-B1527012-7C43-4A41-8C3C-AA74C59C0690Q30249468-EF32DD7D-CE89-4A8E-8BD8-52AD0F5AC3EDQ30276528-6110685B-F367-489F-A354-F07DDE67702EQ33461323-F0C56D7A-AA8C-437C-A175-7A56E4BACFFCQ34831226-CE0896FF-7638-4668-A611-B3589F98692AQ35609697-3A6C49EE-023A-4B13-A562-8538DE36C9E0Q35745038-EA7EA93F-82D5-4230-A016-C93F53A3C985Q35745046-87CE0BB2-499B-4C77-B6A9-9B83FA2EEE78Q35868527-BF292916-9863-46FD-862F-BC8E386DD316Q35923949-B53A08CD-8B50-4E56-B03B-19AD6171E46BQ35923959-DFAA97EA-C087-4FAE-B9D4-4611543DDD88Q35939808-B7BA1C38-5D8F-43A7-97B9-FD1DF5CD4F76Q36398669-49D9A5F4-3615-40CC-AF8A-902E68F424ECQ36661321-1E2D3E57-E4D8-480B-B2CF-EB61CDD75EFEQ38038691-FEA2B727-1F7C-46CF-8D59-C1CB0189D81BQ39255875-5CA18B0A-C277-4279-A897-91B1080F0FF4Q39345800-21713151-C804-49ED-8DFB-8FFC79D83D9BQ39345807-BA3F6859-B9F0-4E7C-AAF3-678CA727E167Q39378798-E5B7E417-BBDE-4F11-9446-1CF3568D9F8BQ39405474-CA6E6C4F-E486-4D70-B312-861ED3DE45FAQ39420822-9AD3AA68-10FD-48F7-8ED1-074EA8EA3C3BQ39496588-A732EE5E-66F7-4F0C-9D0A-65B5059B725FQ42633045-39E92850-6F66-4941-BFA3-46D3D9177208Q42689388-0AB1D3CF-AF25-4B46-9CBB-65B39DF82C6BQ46203790-2DCF95CF-166F-4B11-A745-7BF2DDB5E289Q46642633-186E65A8-1094-4722-B444-7596F477BC99Q48247327-793EE10D-55B8-457F-A083-1B5B227CC521Q48759403-2D88EC6F-367C-4506-8408-64F02A251CF3Q49502751-57D8139E-B948-4359-A502-066586B332A8
P2860
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@en
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@nl
type
label
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@en
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@nl
prefLabel
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@en
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@nl
P2093
P2860
P1476
Onset of symptom relief with r ...... nts with erosive oesophagitis.
@en
P2093
FAST Trial Investigators
L Jokubaitis
M Robinson
S Fitzgerald
P2860
P304
P356
10.1046/J.1365-2036.2002.01181.X
P407
P577
2002-03-01T00:00:00Z